Pelage Pharmaceuticals Appoints New Board Member and Promotes Key Executives In the competitive landscape of regenerative medicine, where innovative solutions for hair loss are increasingly in demand, Pelage Pharmaceuticals is making strategic moves to solidify its position. The company, a…
Positive Top-Line Results for Reblozyl in Alpha-Thalassemia Study Is the treatment landscape for alpha-thalassemia about to change? Bristol Myers Squibb has announced positive top-line results from an ongoing, ex-US, Phase 2 registrational study evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia…
Gilead Sciences Seals $7.8 Billion Deal for Arcellx to Boost CAR T-Cell Therapy In the rapidly evolving landscape of cancer immunotherapies, where breakthroughs are crucial for patient outcomes, Gilead Sciences, Inc. has made a significant move. The biopharmaceutical giant has…
AOP Health Emphasizes Collaboration and Patient-Centered Information on Rare Disease Day 2026 Why is the diagnosis and treatment of rare diseases so challenging? AOP Health, a global enterprise group with roots in Austria, is dedicated to addressing this critical issue.…
Science Corp. and Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership Science Corporation, the pioneering full-stack neural engineering company focused on restoring and extending life, and Neurosoft Bioelectronics, a neural data company utilizing ultra-soft interfaces to achieve full-cortical coverage powering a foundation…
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting AstraZeneca’sCALQUENCE® in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for…
Element Biosciences Introduces VITARI™, Redefining What High-Throughput Sequencing Makes Possible Element Biosciences Inc. today announced VITARI, the first ever high-throughput benchtop sequencing system capable of delivering a high-quality whole genome at $100. With the introduction of VITARI, Element now offers a…
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch ImmunityBio, Inc. a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (nogapendekin alfa inbakicept) in combination…
Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry Henry Schein One, the market leader in dental practice management systems, today announced the launch of AI-driven Image Verify, the latest innovation in…
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine Merck known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world’s top-ranked hospital system, today announced a research and…
Icon Group Deploys ChartCheck Adaptive Across Australia as Radformation Secures USFDA 510(k) Clearance Radformation, a leading provider of intelligent automation solutions for radiation oncology, and Icon Group (Icon), a leading global integrated cancer care provider, today announced the initial deployment of ChartCheck Adaptive,…
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline KalVista Pharmaceuticals, Inc. today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients…
